p21waf1/cip1mda-6 expression in non-small-cell lung cancer: Relationship to survival

American Journal of Respiratory Cell and Molecular Biology

Volumn 18, Issue 2, 1998, Pages 213-217

  Caputi, Mario ^b   Esposito, Vincenzo ^b   Baldi, Alfonso ^b   De Luca, Antonio ^b   Dean, Charity ^b   Signoriello, Guiseppe ^b   Baldi, Feliciano ^b   Giordano, Antonio ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; PROTEIN P53;

ADENOCARCINOMA; ARTICLE; BRONCHUS; CELL NUCLEUS; CHEMISTRY; COHORT ANALYSIS; HUMAN; IMMUNOASSAY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MORTALITY; PATHOLOGY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; BRONCHI; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; COHORT STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; HUMANS; IMMUNOASSAY; LUNG NEOPLASMS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031990912     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.18.2.2937m     Document Type: Article

References (31)

1. Greenblatt, M. S., W. P. Bennett, M. Hollstein, and C. C. Harris. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878.
2. Sang, N., A. Baldi, and A. Giordano. 1995. The roles of tumor suppressors pRb and p53 in cell proliferation and cancer. Mol. Cell. Differ. 3:1-29.
3. Cordon-Cardo, C. 1995. Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Am. J. Pathol. 147:1-16.
4. Lowe, S. W., H. E. Ruley, T. Jacks, and D. E. Housman. 1993. p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
5. Clark, A. R., C. A. Purdie, D. J. Harrison, R. G. Morris, C. C. Bird, M. L. Hooper, and A. T. Wyllie. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852.
6. Kastan, M. B., O. Onkyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311.
7. Zambeletti, G., J. Bargonetti, K. Walker, C. Prives, and A. J. Levine. 1992. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev. 6:1143-1152.
8. Kern, S. E., J. A. Pietenpol, S. Thiagalingam, A. Seimour, K. W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830.
9. Higashiyama, M., O. Doi, K. Kodama, H. Yokouchi, and R. Tateishi. 1994. Retinoblasloma protein expression in lung cancer: an immunohistochemical analysis. Oncology 51:544-551.
10. Iggo, R., K. Gatter, J. Bartek, D. Lane, and A. L. Harris. 1990. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675-679.
11. Passlick, B., J. R. Izbieki, K. Haussinger, O. Thetter, and K. Pantel. 1995. Immunohistochemical detection of p53 protein is not associated with poor prognosis in non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg. 109: 1205-1211.
12. Esposito, V., A. Baldi, A. De Luca, P. Micheli, G. Mazzarella, F. Baldi, M. Caputi, and A. Giordano. 1997. Prognostic value of p53 in non small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum. Pathol. 28:233-237.
13. Esposito, V., A. De Luca, A. Baldi, A. D'aponte, J. Cavallotti, I. Meoli. F. Baldi, M. Caputi, and A. Giordano. 1996. Altered expression of p53 and rb tumor suppressor genes in lung cancer: relationship with survival. Int. J. Oncol. 9:439-443.
14. Harper, J. W., G. R. Adami, N. Wei, K. Keiomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
15. Noda, A., Y. Ning, S. F. Venable, O. M. Pereira-Smith, and J. R. Smith. 1994. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211:90-98.
16. Jang, H., and P. B Fisher. 1993. Use of a sensitive and efficient subtraction hybridization protocol lor the identification of genes differentially regulated during the induction of differentiation in human melanoma cells. Mol. Cell Diff. 1:285-299.
17. el-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Persons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1 a potential mediator of p53 tumor suppression. Cell 75:817-825.
18. MacLachlan, T. K., N. Sang, and A. Giordano. 1995. Cyclins, cyclin-dependent kinases and Cdk inhibitors: implication in cell cycle control and cancer. Crit. Rev. Eukaryot. Gene Express. 5:127-156.
19. Waga, S., G. J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of the cyclin dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578.
20. Flores-Rozas, H., Z. Kelman, F. B. Dean, Z. Q. Pan, J. W. Harper, S. J. Elledge, M O'Donnell, and J. Huwitz. 1994. Cdk-interacting protein 1 directly binds to proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc. Natl. Acad. Sci. USA 91:8655-8659.
21. Li, R., S. Waga, G. J. Hannon, D. Beach, and B. Stillman. 1994. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534-537.
22. Jang, H., J. Lin, Z. Z. Su, F. R. Collart, E. Huberman, and P. B Fisher. 1994. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9: 3397-3406.
23. Johnson, M., D. Dimitro, P. J. Vojta, J. C. Barrett, A. Noda, O. M. Pereira-Smith, and J. R. Smith. 1994. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol. Carcinogen. 11:59-64.
24. Michieli, P., M. Chedid, D. Lin, J. H. Pierce, W. E. Mercer, and D. Givol. 1994. Topological control of p21WAF1/CIP1 expression in normal and neoplaslic tissues. Cancer Res. 54:3391-3395.
25. Shottenfeld, D. 1996. Epidemiology of lung cancer. In Lung Cancer: Principles and Practice. H. I. Pass, J. B. Mitchell, D. H. Johnson, and A. T. Turrisi, editors. Lippincott-Raven, Philadelphia.
26. 1981. Histological Typing of Lung Tumors, 2nd ed. World Health Organization, Geneva. 25-26.
27. Leubwthall, B. G., and R. E. Wittes. 1988. Research Methods in Clinical Oncology. Raven Press, New York. 41.
28. Beahrs, O. H., D. E. Henson, R. V. P. Hutter, and B. J. Kennedy. 1992. Lung. In Manual for Staging of Cancer, 4th ed. American Joint Committee on Cancer, Chicago. 115-122.
29. Marchetti, A., C. Doglioni, M. Barbareschi, F. Buttitta, S. Pellegrini, G. Bertacca, A. Chella, G. Merlo, C. A. Angeletti, P. Dalla Palma, and G. Bevilacqua. 1996. p21 RNA and protein expression in non small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 12:1319-1324.
30. DiGiuseppe, J. A., S. M. Redston, J. C. Yeo, S. E. Kern, and R. H. Hruban. 1995. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am. J. Pathol. 147:884-888.
31. el-Deiry, W. S., T. Tokino, T. Waldman, J. D. Oliner, V. E. Velculescu, M. Burrel, D. E. Hill, E. Healy, J. L. Rees, S. R. Hamilton, K. W. Kinzler, and B. Vogelstein. 1995. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 55:2910-2919.